Department of Gynecologic Oncology, 92276Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Cancer Control. 2023 Jan-Dec;30:10732748231159706. doi: 10.1177/10732748231159706.
Among the three primary gynecological malignancies, ovarian cancer has the lowest incidence but the worst prognosis. Because of the poor prognosis of ovarian cancer patients treated with existing treatments, immunotherapy is emerging as a potentially ideal alternative to surgery, chemotherapy, and targeted therapy. Among immunotherapies, immune checkpoint inhibitors have been the most thoroughly studied, and many drugs have been successfully used in the clinic. CD47, a novel immune checkpoint, provides insights into ovarian cancer immunotherapy. This review highlights the mechanisms of tumor immune evasion via CD47-mediated inhibition of phagocytosis and provides a comprehensive insight into the progress of the relevant targeted agents in ovarian cancer.
在三种主要的妇科恶性肿瘤中，卵巢癌的发病率最低，但预后最差。由于现有治疗方法治疗卵巢癌患者的预后较差，免疫疗法作为手术、化疗和靶向治疗的潜在理想替代方法正在出现。在免疫疗法中，免疫检查点抑制剂研究得最为透彻，许多药物已成功应用于临床。CD47 是一种新型免疫检查点，为卵巢癌免疫治疗提供了新的思路。本综述强调了 CD47 介导的吞噬作用抑制导致肿瘤免疫逃逸的机制，并全面了解了相关靶向药物在卵巢癌中的研究进展。
